ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to... Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.
- Mechanism
- Curator reviewed
ATI-450 is an inhibitor of the MK2 pathway; it also has been observed to have anti-inflammatory activity. This compound likely targets and regulates pro-inflammatory cytokines which in turn will mitigate cytokine release syndrome. The drug is currently being investigated against rheumatoid arthritis, COVID-19, and cryopyrin-associated periodic syndrome (CAPS).
- Formula / weight
- C25H22ClF2N5O3 · 513.93 g/mol (avg)
- Also known as
- (2′S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2′-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5′,6-dimethyl[1(2H),4′-bipyridin]-2-one · (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one
- Code names
- ATI-450 · CDD-450
Resolves to
FQPQMJULRZINPV-UHFFFAOYSA-NSMILESCC1=CC(OCC2=NC=C(F)C=C2F)=C(Cl)C(=O)N1C1=C(C)C=NC(=C1)C1=NC(=NC=C1)C(C)(C)OWhat you can answer from here — as of April 23, 2025
Which drugs share a target with Zunsemetinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account